Assetmark Inc. lifted its holdings in shares of Amgen Inc. (NASDAQ:AMGN – Free Report) by 6.9% in the first quarter, HoldingsChannel.com reports. The fund owned 243,853 shares of the medical research company’s stock after acquiring an additional 15,719 shares during the period. Assetmark Inc.’s holdings in Amgen were worth $85,800,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Anfield Capital Management LLC increased its position in Amgen by 1,000.0% in the fourth quarter. Anfield Capital Management LLC now owns 77 shares of the medical research company’s stock worth $25,000 after buying an additional 70 shares during the last quarter. Dogwood Wealth Management LLC increased its holdings in Amgen by 275.0% in the 4th quarter. Dogwood Wealth Management LLC now owns 75 shares of the medical research company’s stock worth $25,000 after acquiring an additional 55 shares during the last quarter. Board of the Pension Protection Fund purchased a new stake in Amgen in the 4th quarter worth about $26,000. Tower View Wealth Management LLC lifted its holdings in Amgen by 331.6% during the first quarter. Tower View Wealth Management LLC now owns 82 shares of the medical research company’s stock valued at $29,000 after purchasing an additional 63 shares during the last quarter. Finally, Manning & Napier Advisors LLC boosted its position in Amgen by 49.2% during the fourth quarter. Manning & Napier Advisors LLC now owns 97 shares of the medical research company’s stock worth $32,000 after purchasing an additional 32 shares during the period. 76.50% of the stock is currently owned by hedge funds and other institutional investors.
Analyst Upgrades and Downgrades
A number of analysts recently commented on the stock. Freedom Capital upgraded shares of Amgen from a “hold” rating to a “strong-buy” rating in a research note on Thursday, May 7th. Royal Bank Of Canada reissued a “positive” rating on shares of Amgen in a report on Thursday, June 18th. BMO Capital Markets restated an “outperform” rating and set a $400.00 target price on shares of Amgen in a research report on Wednesday, July 1st. Weiss Ratings cut Amgen from a “buy (b)” rating to a “buy (b-)” rating in a research report on Wednesday. Finally, The Goldman Sachs Group set a $389.00 price objective on Amgen in a research note on Friday, June 5th. Two analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, fifteen have issued a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $356.62.
Insider Activity
In other news, SVP Nancy A. Grygiel sold 1,237 shares of the stock in a transaction dated Monday, May 4th. The stock was sold at an average price of $323.73, for a total transaction of $400,454.01. Following the transaction, the senior vice president directly owned 7,009 shares in the company, valued at approximately $2,269,023.57. This represents a 15.00% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 0.85% of the company’s stock.
Amgen Stock Performance
NASDAQ AMGN opened at $371.58 on Friday. Amgen Inc. has a 52-week low of $269.77 and a 52-week high of $391.29. The company has a fifty day moving average of $347.00 and a 200-day moving average of $350.27. The company has a market capitalization of $200.55 billion, a P/E ratio of 25.86, a P/E/G ratio of 3.63 and a beta of 0.41. The company has a debt-to-equity ratio of 5.65, a quick ratio of 1.01 and a current ratio of 1.26.
Amgen (NASDAQ:AMGN – Get Free Report) last released its earnings results on Thursday, April 30th. The medical research company reported $5.15 EPS for the quarter, beating analysts’ consensus estimates of $4.77 by $0.38. Amgen had a return on equity of 137.41% and a net margin of 20.96%.The business had revenue of $8.62 billion for the quarter, compared to analysts’ expectations of $8.58 billion. During the same quarter in the prior year, the firm earned $4.90 earnings per share. The firm’s revenue was up 5.8% on a year-over-year basis. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. As a group, equities research analysts predict that Amgen Inc. will post 22.31 EPS for the current fiscal year.
Amgen Company Profile
Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.
Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.
Featured Stories
- Five stocks we like better than Amgen
- Why Abbott Laboratories Stock Is Suddenly Winning Back Wall Street
- Revving Up Returns: Big Banks Race Through the Rate Plateau
- Why Uber’s Biggest Deal Yet Could Unlock Its Next Growth Phase
- Why Microsoft Is Playing a Different AI Game Than Big Tech—and Cash Flow Is the Test
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN – Free Report).
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.
